As clinical research continues to evolve, so does the way we measure outcomes that matter to patients. For more than two decades, ePROVIDE has been the leading resource for clinical outcome assessment (COA) information, regulatory guidance, and licensing support. Now, sponsors can extend those same trusted insights to the world of digital endpoints, with new access to digital measures and digital health technologies.
Leveraging Atlas, ICON’s most comprehensive platform for digital endpoints, sponsors and researchers can complement traditional COAs with Digital Health Technologies (DHTs) and digital biomarkers, creating more holistic, patient-centered trial strategies.
Why this matters for patient-centered clinical trials
Incorporating both COAs and DHTs together in a protocol provides a richer understanding of patient experience, blending subjective reports with objective, passively collected data. This unified approach strengthens endpoint strategies and increases the likelihood of regulatory success. Mapi Research Trust's collaboration with ICON enables industry experts to:
- De-risk digital endpoint selection through access to Altas, the industry’s most comprehensive library of evidence-based DHTs and digital measures
- Accelerate study design decisions with curated insights into validation, usability, and regulatory readiness
- Design truly patient-centered protocols that measure what matters, both through COAs and through digital technologies